ReadeRx Therapeutics
ReadeRx Therapeutics is developing small molecule inhibitors for the RNA binding protein IGF2BP1 as a novel treatment for cancer.
Ayana Pharma
A late stage company with a unique lipid-based cytotoxic agent cytotoxic agent in preparations for review by FDA for marketing authorization.
Nectin Therapeutics
A biotechnology company devoted to transforming the lives of cancer patients by pioneering the development of next generation immune oncology (IO) therapies.
Splisense
A preclinical company developing novel antisense oligonucleotides for specific genetic mutations in Cytic Fibrosis, a disease with great unmet clinical needs.
HighRAD
HighRAD provides the first Intelligent Computer Assessment Support (iCASTM) system that delivers a trusted, automatic and enriched view of multi-organ imaging longitudinal data to improve healthcare outcomes and help stop disease progression.
HIL Applied Medical ltd
A medical device company with breakthrough laser-based technology that reduces the size, complexity and cost of proton accelerators, marking a significant leap in radiation therapy.
Neoprol
A preclinical company with a unique formulation of the widely used anesthetic agent, Propofol, that provides a solution to the main drawback of the commercial product Diprivan, bacterial contamination.
Lipocure
A preclinical stage company that develops novel liposomal formulations of known drugs for post-surgical pain.
OPhRx
A preclinical company developing novel topical non-invasive formulations of approved drugs to ocular uses, targeting major disease states and clinical needs.
Lipomedix
A Phase Ib company that develops a novel liposomal prodrug of a cytotoxic agent for cancer therapy.
עיינה פארמה קיבלה את אישור ה-FDA לשיווק בארה”ב של תרופה ננוטכנולוגית לטיפול בסרטן
החברה הישראלית והשותף האסטרטגי פאדאגיס ערוכים להשקה מסחרית של התרופה בארה"ב חברת עיינה פארמה, הפועלת מירושלים, הודיעה היום כי תרופת ה- Liposomal HCl-Doxorubicin
SpliSense Secures $28.5 Million in Series B Financing
Round includes up to $8.4 million investment by the Cystic Fibrosis Foundation Funds will be used to advance the Company's mRNA-altering pipeline for the treatment of cystic fibrosis and other genetic pulmonary diseases
בחזית המאבק בסרטן: פיתוח שיסייע למערכת החיסון לזהות ולתקוף גידולים חמקמקים
Nectin Therapeutics, חברה ישראלית המפתחת טיפולים ביולוגיים חדשניים בתחום האימונו-אונקולוגיה, השלימה גיוס של 15 מיליון דולר בסבב B. את הגיוס הובילה Velocity aMoon של קרן אמון, עם השקעה אישית נוספת של מריוס נכט, ובהשתתפות אינטגרה הולדינגס.
aMoon Fund Leads Investment Round in Nectin Therapeutics with Initial Closing of $6M, Total Investment Expected to Reach $15M
Nectin will use the funding for further development of its next-generation immuno-oncology antibodies that help the immune system fight cancer
EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT
First academic BRIDGE Partnership in Israel aims to translate early-stage research from the Hebrew University (“HU”) of Jerusalem into industrial drug development projects
Atox Bio Closes $30 Million Investment
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing
Temasek Leads $25 Million Investment Round in Integra Holdings
Funds will Contribute to Expansion and Development of Integra’s Portfolio, Bringing Hebrew University’s Life Science Innovations to Market
Integra Holdings Closes $3 Million Investment from Guangxi Wuzhou Pharmaceutical Group
Jerusalem, Israel, December 8, 2014 - Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem
Avraham Pharmaceuticals Raises $4.5 Million in Additional Investment Led by Yissum
The capital is intended for the on-going Phase 2b clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; next interim analysis is expected in Q3 2015; final results expected in Q3 2016
Atox Bio Closes $23 Million Investment
Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections